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Purpose: It has been reported that 10% to 20% of children with Kawasaki disease (KD) will not respond 
to intravenous immunoglobulin (IVIG) treatment. In this study, we aimed to identify useful predictors of 
therapeutic failure in children with KD. 
Methods: We examined 309 children diagnosed with KD at the Kyungpook National University Hospital 
and the Inje University Busan Paik Hospital between January 2005 and June 2011. We retrospectively 
reviewed their medical records and analyzed multiple parameters in responders and nonresponders to 
IVIG. 
Results: Among the 309 children, 30 (9.7%) did not respond to IVIG. They had significantly higher 
proportion of neutrophils, and higher levels of aspartate aminotransferase, alanine aminotransferase 
(ALT), total bilirubin, and N-terminal fragment of B-type natriuretic peptide than did responders. IVIG-
nonresponders had a significantly longer duration of hospitalization, and more frequently experienced 
coronary artery lesion, and sterile pyuria.  No differences in the duration of fever at initial treatment or, 
clinical features were noted.
Conclusion: Two independent predictors (ALT≥84 IU/L, total bilirubin≥0.9 mg/dL) for nonresponse 
were confirmed through multivariate logistic regression analysis. Thus elevated ALT and total bilirubin 
levels might be useful in predicting nonresponse to IVIG therapy in children with KD.
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Introduction
Kawasaki disease (KD) is systemic vasculitis that can cause coronary artery com­
plications, and is the most common cause of pediatric acquired cardiac disease in developed 
countries. Some cases are recovered naturally without treatment, but around 15% to 
25% have complications such as coronary aneurysm and coronary artery ectasia. Such 
complications may develop into cardiac infarction, sudden death or ischemic heart 
disease
1,2). The use of high­dose intravenous immunoglobulin (IVIG) and aspirin lowered 
the frequency of coronary artery complications caused by KD to below 5%, and its 
morbidity and mortality also went down
3). Though its mechanism of action is not clear, 
immunoglobulin has a systemic anti­inflammatory action, modulating the production of 
cytokine, neutralizing bacterial superantigen or other etiologic agents, amplifying T­cell 
suppressor activity, and inhibiting the production of antibody
2,3). 
However, 10% to 20% of KD patients do not respond to the conventional therapy and 
have continued fever, and such cases are in need of a different rescue therapy
4,5). In the 
patient group not responding to IVIG and aspirin, the risk of coronary artery compli­
cations is very high. For these problems, many studies have been conducted for the early http://dx.doi.org/10.3345/kjp.2013.56.2.75
HM Park, et al. • Predictors of immunoglobulin-resistant Kawasaki disease
76
identification of patients who do not respond to IVIG. Many 
reports have been made particularly in Japan, and they reported 
involved factors such as pediatric patients’ age, dura tion between 
the onset of fever and the administration of IVIG, sodium level, 
proportion of neutrophil, C­reactive protein (CRP), platelet count
6), 
albumin
7), total bilirubin, aspartate amino  transferase (AST)
8), and 
alanine aminotransferase (ALT)
9), and developed risk­scoring 
systems using several factors. Never theless, there are no agreed 
factors for predicting patients not responding to IVIG.
Thus, the present authors conducted this study in order to find 
clinical patterns and laboratory findings important for predicting 
patients not responding to IVIG.
Materials and methods
1. Patients
The subjects of this study were 309 patients diagnosed with 
KD and treated at the Kyungpook National University Hospital 
and the Inje University Busan Paik Hospital during the period 
from January 2005 to June 2011. KD was diagnosed according 
to the criteria published by American Heart Association in 
2004
2). For all the patients, we collected samples on the day of 
admission or before immunoglobulin treatment, and measured 
hemoglobin (Hb), white blood cell, proportion of neutrophil, 
platelet count, erythrocyte sedimentation rate, CRP, AST, ALT, 
sodium, potassium, total protein, albumin, total bilirubin, total 
cholesterol, triglyceride, high density lipoprotein (HDL), and 
N­terminal fragment of B­type natriuretic peptide (NT­proBNP). 
All of the patients were administered with IVIG (2 g/kg) and 
high­dose aspirin (80—100 mg/kg/day). Those who showed 
improvement in fever and other symptoms after the admini­
stration of IVIG were classified as IVIG­responders, and those 
whose fever continued for over 36 hours or who had re  cru­
descent fever (temperature≥38.0℃ axillary or rectally) were 
classified as IVIG­nonresponders. In addition, echo cardio graphy 
was performed to measure coronary artery size at diag  nosis. 
Coronary artery lesion was defined as follows; 1) coronary artery 
diameter had a Z­score≥2.5, 2) size of coronary artery had 1.5 
times larger than other lesions
2).
2. Risk-scoring systems 
The parameters of Kobayashi score
6) are as follows: 1) sodium 
≤133 mmol/L, 2 points; 2) days of illness at initial treatment ≤4 
days, 2 points; 3) AST ≥100 IU/L, 2 points; 4) % of neutrophil≥80, 
2 points; 5) CRP≥10 mg/dL, 1 point; 6) age≤12 months, 1 point; 
and 7) platelet count≤300×10
3/mm
3, 1 point. The parameters 
of Egami score
9) are as follows: 1) ALT≥80 IU/L, 2 points; 2) 
illness days≤4 days, 1 point; 3) CRP≥8 mg/dL, 1 point; 4) age≤ 
6 months, 1 point; and 5) platelet count≤300×10
3/mm
3, 1 point. 
The Sano scoring system
8) is as follows: 1) AST≥200 IU/L, 1 
point; 2) CRP≥7 mg/dL, 1 point; and 3) total bilirubin≥0.9 mg/
dL, 1 point.
By applying each scoring system to our data, we divided the 
subjects into low­risk and high­risk groups and obtained sen­
sitivity and specificity. 
3. Statistical analysis
The groups were compared through Mann­Whitney U­test 
and Student’s t­test. And comparison according to age, weight 
and gender and the comparison of the frequency of coronary 
artery lesion were made through chi­square test using SPSS 
ver. 12.0 (SPSS Inc., Chicago, IL, USA). We determined signifi­
cant parameters by univariate analyses, and then the cutoff 
values of these factors were obtained using receiver operating 
characteristic (ROC) curve. With these factors in addition to 
age (not older than 12 months), the duration of fever at the 
beginning of treatment (not longer than 4 days) and gender 
(male), which are factors suggested as the predictors of IVIG­
resistant KD suggested in the previous reports
6­9), we performed 
multivariable logistic regression analysis. In all analyses, the 
statistical significance of difference was accepted if P<0.05.
4. Ethics statement
The study protocol was reviewed and approved by the Insti­
tutional Review Board (IRB) of the Inje University Busan Paik 
Hospital (IRB No. 12­053). 
Results
1. Comparison of clinical findings between groups
Among the 309 patients, 30 (9.7%) did not respond to IVIG. 
Between the IVIG­responders and IVIG­nonresponders, no 
difference was observed in age, gender, and the duration of 
fever on diagnosis (P=0.987, P=0.195, and P=0.737). The clinical 
pattern of KD was not different between the two groups, but the 
frequency of sterile pyuria was higher in the IVIG­nonr esponders 
(19/30, 63.3%) than in the IVIG­responders (67/279, 24.0%), 
and hospitalization time was also around two times longer in 
the IVIG­nonresponders (P<0.001). The frequency of coronary 
artery lesion was 43.3% (13/30) in the IVIG­nonre sponders, more 
frequent than 6.8% (19/279) in the IVIG­respon ders (P<0.001) 
(Table 1). 
Of the 30 IVIG­nonresponders, 22 were retreated with IVIG (2 
g/kg). Six did not respond to IVIG­retreatment were given pulse 
methylprednisolone (30 mg/kg dose for 3 days), and 2 who did 
not respond to IVIG and steroid was treated with infli ximab (5 77 http://dx.doi.org/10.3345/kjp.2013.56.2.75
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mg/kg).
2. Comparison of biological markers and risk-scoring systems 
between groups
AST, ALT, total bilirubin, % neutrophils, and NT­proBNP 
were significantly higher in the IVIG­nonresponders than in the 
IVIG­responders, and sodium level and HDL level were lower in 
the IVIG­nonresponders than in the IVIG­responders. Previously 
reported risk factors such as CRP, platelet count, and albumin 
were not significantly different in this study (Table 2). When 
data on our patients was applied to Kobayashi score
6), Sano 
score
8), Egami score
9), and which are risk­scoring systems for 
predicting IVIG­resistant KD, were significantly higher in the 
IVIG­nonresponder group. The sensitivity and specificity of the 
Kobayashi model was 60% and 74%, respec tively, and those of 
the Egami model were 57% and 77%, re  spectively. The Sano 
model showed sensitivity of 60% and specificity of 90% (Table 3).
3. Cutoff values of biomarkers by ROC curve
For each biomarker, the cutoff value was decided by the ROC 
curve. When the cutoff value of % neutrophils for identifying 
IVIG­nonresponders was set to 76%, the area under the ROC 
curve was 0.689 (95% confidence interval [CI], 0.580 to 0.798), 
sensitivity was 63%, and specificity was 74%. When the cutoff 
value of AST was 56 IU/dL, the area under the ROC curve 
was 0.683 (95% CI, 0.564 to 0.801), sensitivity was 60%, and 
specificity was 71%. For ALT, at cutoff value of 84 IU/dL, the 
area under the ROC curve was 0.751 (95% CI, 0.654 to 0.847), 
sensitivity was 73%, and specificity was 75%. At cutoff value 0.9 
mg/dL of total bilirubin, the area under the ROC curve was 0.739 
(95% CI, 0.627 to 0.852), sensitivity was 70%, and speci ficity was 
86%. At cutoff value 136 mmol/L of sodium level, the area under 
the ROC curve was 0.706 (95% CI, 0.626 to 0.786), sensitivity 
was 70%, and specificity was 59%. 
4. Independent predictors of IVIG-nonresponders
According to the results of multivariable logistic regression 
analysis, the independent risk factors of IVIG­nonresponders 
were ALT≥84 IU/dL and total bilirubin≥0.9 mg/dL. The odds 
ratio was 3.8 for ALT, and 5.3 for total bilirubin. Having both 
of the two predictors (ALT≥84 IU/dL, total bilirubin≥0.9 mg/
dL) in laboratory findings showed higher sensitivity and speci­
ficity (63% and 90%, respectively) than the existing models in 
predicting KD patients not responding to initial IVIG (Table 4).
Table 1. Characteristics of patients between IVIG-responders and IVIG-
nonresponders 
Characteristic IVIG-responders 
(n=279)
IVIG-nonresponders 
(n=30) P value
Age (mo) 26.0 (13–44) 27.5 (16.8–38.3) 0.987
Male 142 (50.9) 19 (63.3) 0.195
Duration of fever (day) 5 (4–6) 5 (4–6) 0.737
Hospitalization time (day) 6 (5–7) 11 (9–14) <0.001
Sterile pyuria 67 (24.0) 19 (63.3) <0.001
CAL 19 (6.8) 13 (43.3) <0.001
Values are presented as median (25th to 75th percentiles) or number (%). 
IVIG, intravenous immunoglobulin; CAL, coronary artery lesion.
Table 2. Comparison of biological markers between IVIG-responders 
and IVIG-nonresponders
Variable IVIG-responders IVIG-nonresponders P value
Hemoglobin (g/dL) 11.6±1.1 11.4±1.2 0.366
WBC (×10
3/mm
3) 13.7±5.1 14.7±6.0 0.318
% of neutrophils   64.5±15.7 74.2±15.7 0.001
Platelet (×10
3/mm
3) 398.0±141.7 348.0±143.4 0.307
ESR (mm/hr) 54.1±26.3 60.2±27.0 0.227
CRP (mg/dL) 7.3±8.0 9.1±5.0 0.200
AST (IU/L) 64.2±101.5 125.8±118.0 0.009
ALT (IU/L) 81.7±122.8 164.0±110.5 <0.001
Sodium (mmol/L) 137.2±3.5 134.7±2.9 <0.001
Potassium (mmol/L) 4.5±2.4 4.3±0.5 0.599
Total protein (g/dL) 6.8±0.6 6.7±0.9 0.686
Albumin (g/dL) 4.0±2.0 3.5±0.5 0.226
Total bilirubin (mg/dL) 0.7±1.1 1.8±1.5 0.001
Total cholesterol (mg/dL) 136.5±27.3 130.0±31.4 0.265
Triglyceride (mg/dL) 106.9±43.8 134.6±70.5 0.065
HDL (mg/dL) 33.8±12.3 24.7±14.3 0.001
NT-proBNP (pg/mL) 920.6±1067.3 1,787.5±1629.8 0.017
Values are presented as mean±standard deviation. 
IVIG, intravenous immunoglobulin; WBC, white blood cell; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; HDL, high density lipoprotein.
Table 3. Comparison between IVIG-responders and IVIG-nonresponders 
applied to risk-scoring systems 
Variable IVIG-responders 
(n=279)
IVIG-nonresponders
(n=30) P value
Kobayashi score* 2.4±1.9 4.4±2.3 <0.001
Low risk (0–3) 206 (74) 12 (40)
High risk (≥4)  73 (26) 18 (60)
Egami score
† 1.6±1.2 2.6±1.3 <0.001
Low risk (0–2) 214 (77) 13 (43)
High risk (≥3)  65 (23) 17 (57)
Sano score
‡ 1.1±0.6 1.8±0.6 <0.001
Low risk (0–1) 252 (90) 12 (40)
High risk (≥2)  27 (10) 18 (60)
Values are presented as mean±standard deviation or number (%). 
*Scores calculated by Kobayashi predictive system
6). 
†Scores by Egami system
9). 
‡Scores by Sano system
8).http://dx.doi.org/10.3345/kjp.2013.56.2.75
HM Park, et al. • Predictors of immunoglobulin-resistant Kawasaki disease
78
Discussion
From the results of this study, we found two predictors (ALT≥ 
84 IU/dL and total bilirubin≥0.9 mg/dL) for KD not responding 
to initial IVIG treatment. In addition, the frequency of coronary 
artery lesion was much higher in IVIG­resistant KD, and pulse 
methylprednisolone and anti­tumor necrosis factor (TNF)­α 
monoclonal antibody (infliximab) were found to be useful and 
effective as rescue therapy. 
Research is being made actively for reducing the duration of 
fever and coronary artery lesions through early detection and 
treatment of patients not responding to IVIG, who occupy around 
10% to 20% of KD. Still, no agreed risk factors have been 
found. Many of studies on such risk factors were conducted 
with Japanese patients, and Kobayashi et al.
6), Sano et al.
8), 
Egami et al.
9), etc. proposed scoring system for predicting IVIG­ 
nonresponders using various parameters. When these risk­
scoring systems were applied to the subjects of our study, spe­
cificity was high (74% to 90%) but sensitivity was low (57% to 
60%), so they had difficulty in screening out high­risk patients 
who need intensive treatment. After all, there is a problem 
in applying the risk­scoring systems, which are effective to 
Japanese pediatric patients, to Korean pediatric patients due 
to difference in genetic factors between Japanese and Korean 
patients.
In other studies, Ashouri et al.
7) reported risk predictors such 
as high percent band count, low albumin and the presence 
of coronary artery lesions. Tremoulet et al.
10) mentioned high 
percent band count, long illness day, high gamma­glutamyl 
transferase, and low age­adjusted Hb as the risk predictors of 
IVIG­nonresponders. In Korea as well, Do et al.
11) reported that 
low albumin, low sodium, and high neutrophil proportion were 
significant in the IVIG­resistant group. Changes in these biomarkers 
are the effects of diverse cytokines (inter leukin [IL]­1β, TNF­α, 
interferon (IFN)­γ, IFN­α, IL­4, IL­6, IL­8, IL­10, transforming 
growth factor­β, matrix metalloproteinase, vas cular endothelial 
growth factor (VEGF) increasing at the early stage
2,5). The 
elevation of VEGF induces the increase of vascular leakage, 
which in turn, decreases albumin. Furthermore, cytokine­
activated natural killer cells accumulate in vascular endo  thelium 
and along liver sinusoids. As a result, inflamma tion of hepatic 
reticuloendothelial system and biliary tract occurs, that increases 
liver enzyme and total bilirubin
6,12). The accurate pathogenesis 
of hyponatremia in KD is unknown but is explained by the 
inappropriate secretion of antidiuretic hormone caused by 
cerebral vasculitis and the direct renal loss of sodium resulting 
from the renal involvement of KD
13). 
As in the previous studies
6­9), there were statistical differences 
in sodium level, liver enzymes (AST, ALT), total bilirubin, 
and neutrophil proportion in our study. The other parameters 
mentioned above were not significantly different. Moreover, 
high frequency of sterile pyuria, low HDL were observed in the 
IVIG­nonresponder group. KD patients show abnormal urinary 
findings such as proteinuria, hematuria and sterile pyuria, and 
severe cases may have interstitial nephritis, acute renal failure, 
etc., rarely. Sterile pyuria is caused less by urethritis than by 
renal parenchymal injury and inflammation in KD, and it is also 
closely associated with cytokines
14). KD causes also abnormalities 
in lipid metabolism due to the effects of cytokines such as TNF­α, 
IL­1 and IL­6. With the decrease of HDL, triglyceride increases. 
TNF­α and IL­1 decreases HDL by damaging the activity of 
lipoprotein lipase, and increases triglyceride through decreasing 
circulating lipoprotein and increasing hepatic lipid synthesis
15­17). 
In our study, HDL was significantly different between the two 
groups, but because the value of lipid profile is affected by diet it 
may have a limitation as a predictive marker of IVIG­responders 
and IVIG­nonresponders.
NT­proBNP, a widely used biomarker of cardiovascular 
disease, is cardiac hormone secreted by the ventricles in response 
to sheer stress from the overload of body fluid and pressure. 
It is involved in diuresis, natriuresis, and arterial and venous 
dilatation and plays the role of regulating myocardial prolife­
ration and hypertrophic response
18,19). NT­proBNP is a very 
important biomarker for the diagnosis, treatment and prognosis 
of heart failure in adults, and is a predictor of cardiac functions 
in patients after cardiac infarction
20,21). In pediatric patients as 
well, NT­proBNP is a significant biomarker for heart failure, 
congenital heart disease with left­to­right shunt, cyanotic heart 
disease, right heart disease, secondary right heart disease induced 
by pulmonary hypertension and pulmonary regurgitation, and 
allograft disease after heart transplantation
22­24). Not as in other 
febrile illnesses, what is more, it increases at the acute stage 
of KD and decrease at the convalescent stage, so is useful for 
diagnosis
25). Among cytokines, TNF­α and IL­1β accelerate the 
secretion of NT­proBNP, and secondarily the secretion of NT­
proBNP is accelerated by sub clinical myocarditis and ischemia 
Table 4. Multivariate analysis of IVIG-nonresponders
Risk factor Odds ratio (95% CI) P value
Age (≤12 mo) 0.986 (0.301–3.228) 0.982
Illness at initial treatment (≤4 days) 0.924 (0.363–2.352) 0.868
Gender (male) 1.937 (0.790–4.748) 0.148
Neutrophil (≥76%) 1.945 (0.693–5.459) 0.206
Sodium (≤136 mmol/L) 0.657 (0.253–1.709) 0.389
AST (≥56 IU/L) 0.546 (0.172–1.730) 0.304
ALT (≥84 IU/L) 3.780 (1.132–12.616) 0.031
Total bilirubin (≥0.9 mg/dL) 5.330 (1.721–16.505) 0.004
Sterile pyuria 1.714 (0.634–4.633) 0.288
IVIG, intravenous immunoglobulin; CI, confidence interval; AST, aspartate ami-
notransferase; ALT, alanine aminotransferase.79 http://dx.doi.org/10.3345/kjp.2013.56.2.75
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in KD
26). In this study, NT­proBNP was statistically significantly 
higher in the IVIG­non responder group. Because its variation is 
large according to age, however, NT­proBNP may be considered 
clinically but has a limitation in being used as a predictor
22).
With excluding parameters which have problems in being 
used as a predictor, we could obtain the predictors of KD non­
responsive to IVIG using risk factors confirmed from our data 
and several factors suggested in previous studies. ALT≥84 IU/
dL and total bilirubin≥0.9 mg/dL can be used as important 
independent risk factors for IVIG­resistant KD. These results 
imply that severe inflammation spread to the hepatic reticulo­
endothelial system by the impact of several cytokines and 
natural killer cells in the IVIG­nonresponder group. 
Limitations of this study are that the number of IVIG­nonre­
sponders was too small to represent the sample, and that the 
study was conducted retrospectively at two medical centers. 
In addition, echocardiography for diagnosing coronary artery 
lesions was performed by different examiners.
In conclusion, IVIG and high dose aspirin are established 
treatment methods of KD. There are still the controversial 
questions of what risk factors predict patients not responding 
to IVIG and what additional treatments should be applied to 
reduce coronary artery lesions. If a large­scale study is conducted 
with the whole population of KD pediatric patients, we may find 
the risk factors of KD not responding to IVIG. Then, we may be 
able to suggest new treatment guidelines different from existing 
treatment methods and to prevent coronary artery complications 
caused by KD.
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